
AbbVie’s Upadacitinib Clears Regulatory Hurdle for Vitiligo Treatment
The European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending upadacitinib as a systemic treatment for non-segmental vitiligo. If the European Commission grants final approval, the drug would become the first systemic medication specifically indicated for the chronic autoimmune condition.






















